CTPS1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3610169	0.59	12/20
SCHEMBL3613532	0.64	11/20
SCHEMBL393578	0.53	10/20
SCHEMBL5604178	0.55	9/20
SCHEMBL3605392	0.40	9/20
SCHEMBL3621235	0.52	8/20
SCHEMBL3623344	0.50	8/20
SCHEMBL3612854	0.49	8/20
SCHEMBL3620030	0.48	8/20
SCHEMBL7137179	0.47	8/20
SCHEMBL3609832	0.46	8/20
SCHEMBL3622272	0.46	8/20
SCHEMBL7091495	0.45	8/20
SCHEMBL3622882	0.42	8/20
SCHEMBL5215989	0.56	7/20
SCHEMBL3621498	0.50	7/20
SCHEMBL3618399	0.49	7/20
SCHEMBL8249060	0.45	7/20
SCHEMBL3616711	0.41	7/20
SCHEMBL3621166	0.41	7/20

Clinical trials — most relevant to CTPS1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria	PHASE3	ACTIVE_NOT_RECRUITING
Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy	PHASE2/PHASE3	UNKNOWN
A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of Lung	PHASE2	COMPLETED
Prospective Phase II Randomized Trial of Postoperative Adjuvant Chemotherapy in Patients With High Risk Colon Cancer	PHASE2	UNKNOWN
Hereditary Sensory Neuropathy Serine Trial	PHASE2	UNKNOWN
Homocystinuria: Treatment With N-Acetylcysteine	PHASE2	COMPLETED
Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer	PHASE2	UNKNOWN
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma	PHASE1/PHASE2	RECRUITING
A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE2	UNKNOWN
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides	PHASE1	COMPLETED
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors	PHASE1	COMPLETED
TS Overexpression in SCLC: Mechanism and Therapeutic Targeting	nan	COMPLETED
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH)	nan	COMPLETED
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study	nan	COMPLETED
Genetic and Environmental Determinants of Triglycerides (GOLDN)	nan	COMPLETED
In Vivo Metabolism of apoB-containing Lipoproteins in ANGPTL3 Deficient Subjects	nan	UNKNOWN
Screening of Healthy Adults for Genetic Variations That Control Fatty Acid Processing	nan	COMPLETED
Familial Partial Lipodystrophy Study	nan	COMPLETED
Identification of a New Gene Involved in Hereditary Lipodystrophy	nan	COMPLETED
The LD Lync Study - Natural History Study of Lipodystrophy Syndromes	nan	RECRUITING
Genetic Hallmarks of Patients With Congenital Portosystemic Shunts and Portopulmonary Hypertension	nan	NOT_YET_RECRUITING
Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions	nan	RECRUITING
Genetic and Metabolic Disease in Children	nan	RECRUITING
Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome	nan	RECRUITING
Droplet Digital PCR and PCR-free BIOSensors for the Detection of Resistance-associated SNPs in Pneumocystis Jirovecii	nan	ACTIVE_NOT_RECRUITING
Gene Modifiers of Cystic Fibrosis Lung Disease	nan	ACTIVE_NOT_RECRUITING
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
Tissue Sample Study for Mitochondrial Disorders	nan	ENROLLING_BY_INVITATION
Genetic Epidemiology of Sarcoidosis	nan	COMPLETED
for Adipose Tissue DIabetes VAriants (fATDIVA)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CTPS1 binder may also engage these)

Protein	Name	Similarity
Q3ANY4	—	1.000	Q3ANY4 →
Q7ZXP9	—	1.000	Q7ZXP9 →
Q5XHA8	—	1.000	Q5XHA8 →
Q1RMS2	—	1.000	Q1RMS2 →
A2C5F9	—	1.000	A2C5F9 →
O74638	—	1.000	O74638 →
P70698	—	0.999	P70698 →
CTPS2	CTP synthase 2	0.999	landscape →
Q1IKC9	—	0.999	Q1IKC9 →
Q5F3Z1	—	0.999	Q5F3Z1 →
Q7NKF4	—	0.999	Q7NKF4 →
A6ZQ59	—	0.998	A6ZQ59 →
Q1DDB7	—	0.998	Q1DDB7 →
Q6FUD0	—	0.998	Q6FUD0 →
Q9VUL1	—	0.998	Q9VUL1 →
P38627	—	0.998	P38627 →
Q8F3J3	—	0.998	Q8F3J3 →
Q54V77	—	0.998	Q54V77 →
B2JIX2	—	0.997	B2JIX2 →
Q0I677	—	0.997	Q0I677 →
Q8XIB3	—	0.997	Q8XIB3 →
A3ML79	—	0.996	A3ML79 →
Q6PEI7	—	0.996	Q6PEI7 →
B9KHF1	—	0.996	B9KHF1 →
B3QRL0	—	0.996	B3QRL0 →
Q13X05	—	0.996	Q13X05 →
A0K8N3	—	0.996	A0K8N3 →
A5FHA4	—	0.996	A5FHA4 →
A4SXE7	—	0.995	A4SXE7 →
A8FSS7	—	0.995	A8FSS7 →